How Do I Start Longevity Medication?
Longevity medicine, also known as regenerative medicine, is a revolutionary field that aims to enhance our health and increase our ...
CSI: OPIOIDs: A Call for Participants
The CSI:OPIOIDs research study team carries out interviews with anyone who lost a loved one to suicide following an opioid ...
Imprisoned Physician Targeted for Treating Opioids Gets New Trial
The Supreme Court ruling has begun to protect physicians, though the media narrative might not want to believe it.
Patients: Start ‘Loud Budgeting’
In today's complex healthcare landscape, patients often find themselves burdened with unexpected medical expenses.
Post-op Pain Relief for Mr. Merrick Garland?
Attorney General Merrick Garland is undergoing back surgery. We ponder what type of pain relief he will receive.
Syphilis: Back With a Vengeance
Injectable penicillin is the go-to treatment for syphilis and the only treatment considered safe for pregnant people with the disease.
Suicide is an Epidemic Most Physicians Cannot Treat
Suicide has reached epidemic proportions in the US − yet medical students still don’t receive adequate training to treat suicidal ...
SAMHSA Makes Permanent Increased Access to OUD Medications
The Biden administration announced that policies put in place during the pandemic will continue permanently.
How False Narratives Affect LQBTQ+ Rights
We expose the rhetorical tricks and strategic deceptions used to skew clinical science against marginalized groups.
A Patient’s Existential Angst
Healthcare, as we see it, is defined through broad statistics. For the patient, healthcare is the unique day to day ...
Hidden Flaw in Observational Studies
One way in which observational studies can be manipulated is by playing with the time horizon of the study data.
Why Nobody Wants to be a PCP
It’s hard to know if any policy is working given that the data on primary care shortage areas has been ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more